{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:17Z","timestamp":1793414117497,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jacbts.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T11:19:02Z","timestamp":1620040742000},"page":"485-496","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx"],"prefix":"10.1016","volume":"6","author":[{"given":"Erin S.","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Tami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuolung","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Brambatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam E.","family":"Mullick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Geary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2021.04.004_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib3","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A\u00a0randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-9149(88)80087-0","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"62","author":"Swedberg","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.04.004_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2021.04.004_bib8","doi-asserted-by":"crossref","first-page":"f360","DOI":"10.1136\/bmj.f360","article-title":"Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials","volume":"346","author":"Makani","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jacbts.2021.04.004_bib9","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00219.2016","article-title":"Intracrine angiotensin II functions originate from noncanonical pathways in the human heart","volume":"311","author":"Ferrario","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nrneph.2011.29","article-title":"Limitations of angiotensin inhibition","volume":"7","author":"Nobakht","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jacbts.2021.04.004_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/euhj.1999.1740","article-title":"Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure","volume":"21","author":"Roig","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2021.04.004_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11906-016-0643-8","article-title":"New evidence supporting the use of mineralocorticoid receptor blockers in drug-resistant hypertension","volume":"18","author":"Narayan","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jacbts.2021.04.004_bib15","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1021\/acs.jmedchem.5b01948","article-title":"Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes","volume":"59","author":"Prakash","year":"2016","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jacbts.2021.04.004_bib16","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.jacbts.2021.04.004_bib17","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two\u00a0randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.04.004_bib18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacbts.2021.04.004_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc3-conjugated 2\u2019-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucl Acid Ther"},{"key":"10.1016\/j.jacbts.2021.04.004_bib21","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/HYPERTENSIONAHA.117.09755","article-title":"Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury","volume":"70","author":"Mullick","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2021.04.004_bib22","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacbts.2021.04.004_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacbts.2021.04.004_bib24","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ackd.2014.03.005","article-title":"Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease","volume":"21","author":"Yamout","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.jacbts.2021.04.004_bib25","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(15)00264-0","article-title":"Spironolactone for resistant hypertension--hard to resist?","volume":"386","author":"Sternlicht","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2021.04.004_bib26","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib27","first-page":"1065","article-title":"Aliskiren in type 2 diabetes and cardiorenal end points","volume":"368","author":"Pfeffer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacbts.2021.04.004_bib28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ejhf.896","article-title":"Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial","volume":"20","author":"Kristensen","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacbts.2021.04.004_bib29","first-page":"183","article-title":"Molecular and pathophysiological features of angiotensinogen: a mini review","volume":"4","author":"Wu","year":"2011","journal-title":"N\u00a0Am J Med Sci (Boston)"},{"key":"10.1016\/j.jacbts.2021.04.004_bib30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0008-6363(01)00479-5","article-title":"Renin angiotensin system and gender differences in the cardiovascular system","volume":"53","author":"Fischer","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2021.04.004_bib31","doi-asserted-by":"crossref","first-page":"A13913","DOI":"10.1161\/circ.142.suppl_3.13913","article-title":"Single dose safety, pharmacokinetics, and pharmacodynamics of a potent PCSK9 synthesis inhibitor, AZD8233, in subjects with elevated LDL cholesterol (abstr.)","volume":"142","author":"Nilsson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2021.04.004_bib32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and\u00a0sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2021.04.004_bib33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1161\/HYPERTENSIONAHA.118.11084","article-title":"Recent advances in therapeutic vaccines to treat hypertension","volume":"72","author":"Nakagami","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.jacbts.2021.04.004_bib34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MNH.0000000000000586","article-title":"Targeting angiotensinogen with RNA-based therapeutics","volume":"29","author":"Ren","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jacbts.2021.04.004_bib35","first-page":"429","article-title":"Endpoints in heart failure drug development: history and future","volume":"8","author":"Fiuzat","year":"2020","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacbts.2021.04.004_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/ATVBAHA.118.311817","article-title":"Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report","volume":"39","author":"Ye","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacbts.2021.04.004_bib37","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1194\/jlr.M093252","article-title":"Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis","volume":"60","author":"Tao","year":"2019","journal-title":"J\u00a0Lipid Res"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21001704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X21001704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:23:41Z","timestamp":1762820621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X21001704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2452302X21001704"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.04.004","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}